Editorials - (2025) Volume 7, Issue 2
For over three decades, antiretroviral therapy (ART) has been the cornerstone of HIV treatment, transforming a once-lethal diagnosis into a manageable chronic condition. Yet, as science advances and the needs of people living with HIV evolve, researchers and clinicians are looking beyond viral suppression toward a more holistic and innovative therapeutic landscape. The next frontier in HIV therapeutics encompasses long-acting formulations, immune-based therapies, gene editing, and precision medicine—all aimed at improving quality of life, reducing stigma, and ultimately achieving a cure.
Abstract
For over three decades, antiretroviral therapy (ART) has been the cornerstone of HIV treatment, transforming a once-lethal diagnosis into a manageable chronic condition. Yet, as science advances and the needs of people living with HIV evolve, researchers and clinicians are looking beyond viral suppression toward a more holistic and innovative therapeutic landscape. The next frontier in HIV therapeutics encompasses long-acting formulations, immune-based therapies, gene editing, and precision medicine—all aimed at improving quality of life, reducing stigma, and ultimately achieving a cure.
Published: 26-Sep-2025, DOI: 10.35248/JHAR.25.7(2).001
Copyright:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
